BenevolentAI is a clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting-edge science to decipher complex disease biology, identify novel drug targets, and develop new medicines. Their proprietary Benevolent Platform™ aims to accelerate the journey from data to medicine, focusing on areas with high unmet patient needs. By transforming how drugs are discovered, BenevolentAI strives to bring more effective therapies to patients faster and more efficiently.
The London headquarters serves as the central hub for research and development, corporate strategy, AI platform development, and global operations management.
Modern office space designed for collaboration, housing both computational and scientific teams. Proximity to leading academic institutions and biomedical research facilities.
A dynamic, innovative, and science-driven environment that encourages cross-disciplinary collaboration between AI specialists, biologists, chemists, and drug developers. Emphasis on continuous learning and tackling complex challenges.
Its location in London provides access to a rich talent pool, world-class research institutions, and the European financial markets, supporting its growth and innovation.
BenevolentAI operates with a significant presence in Europe and North America. Its London headquarters drives overall strategy and AI platform development, the Cambridge (UK) site focuses on experimental drug discovery, and the New York office supports US operations and business development. This global footprint enables access to diverse talent pools, research collaborations, and key pharmaceutical markets.
4-8 Maple Street
London
England
United Kingdom
Address: 7 World Trade Center, 250 Greenwich St, New York, NY 10007, USA
To expand BenevolentAI's presence in North America, fostering partnerships, accessing US talent, and engaging with the American financial and biopharma communities.
Address: Babraham Research Campus, Cambridge, CB22 3AT, UK
To anchor BenevolentAI's experimental science capabilities within one of the world's foremost biotech hubs, facilitating collaborations and access to specialized talent and infrastructure.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BenevolentAI' leadership includes:
BenevolentAI has been backed by several prominent investors over the years, including:
BenevolentAI has experienced key leadership transitions, including the appointment of a new CEO in May 2023 and the announcement of an incoming CFO expected in Q3 2024.
Discover the tools BenevolentAI uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BenevolentAI commonly uses the email format combining the employee's first name initial followed by their last name, or first name separated by a dot from the last name, at the benevolent.ai domain. Variations may exist.
[first_initial][last]@benevolent.ai or [first].[last]@benevolent.ai
Format
jdoe@benevolent.ai
Example
80%
Success rate
BenevolentAI Press Release • April 24, 2024
BenevolentAI announced the appointment of Catherine Isted as Chief Financial Officer (CFO) and executive Director of the Company. Catherine is expected to join BenevolentAI and the Board in Q3 2024, succeeding Nicholas Keher....more
BenevolentAI Press Release • March 20, 2024
BenevolentAI reported its financial results for 2023, highlighting progress in its pipeline, strategic collaborations, and advancements in its AI platform. Revenue was £10.6 million, primarily from collaborations....more
BenevolentAI Press Release • September 26, 2023
BenevolentAI announced positive topline results from the Phase Ia first-in-human clinical trial for BEN-8744. The study demonstrated that BEN-8744 was safe and well-tolerated at all dose levels tested....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BenevolentAI, are just a search away.